The world's earliest test for Alzheimer's biomarkers
1085045195K190
Tags
B2C<500KSeedCinematicProduct launchB2BUS
TLVC Rating
2.60
Hook
Editing / Creativity
Copy
Sentiment of launch
Distribution strategy
Community Rating
No ratings yet
to rate this launch.
Saccade is building a 15-minute VR-based assessment that screens for Alzheimer's by measuring oculomotor patterns, the small, involuntary eye movements that shift up to 15 years before symptoms appear . The test is designed for longevity clinics and works through a patent-pending attachment that connects to any VR headset on the market and captures eye movement patterns while patients perform visual tasks designed by neurologists. Those signals are then run against an ML model to produce a risk score that clinicians can act on.
The timing matters because Alzheimer's testing today is bottlenecked around the onset of symptoms, when the damage is already done, and the FDA-approved drugs released in 2024 only slow the disease rather than reverse it . Catching the earliest biomarkers opens a longer window for intervention, and Saccade routes classified patients to the new drug regimens and to longevity or neurology practices depending on their stage of decline.
The company is based in San Francisco and part of Y Combinator's Fall 2026 batch . It was founded by Shreyas Bhardwaj , who previously built medical devices for hospitals and worked as a soft robotics researcher before starting the company.
Comments (15)
Sign in to join the discussion.
N
Nadia Osorio18h ago
The 15-year hook in the first line is doing serious work. Half the people in that reply thread learned something new before the second sentence.
K
Kenji T.18h ago
Eye-tracking for prodromal AD has decades of literature behind it but almost nothing shipped to clinics. Curious which saccadic metrics you're keying on, antisaccade latency or something more composite?
T
Thabo M.17h ago
The cruelest diseases are the ones that steal time you didn't know you had. Giving people back 15 years of warning is the whole game.
C
contrarian carl18h ago
Market shrinks the second a disease-modifying therapy actually works at scale. You're racing against your own TAM.
P
Priya Ramaswamy18h ago
Been watching this space for a while and the moat is distribution into neurology clinics, not the test itself. Who's your first channel partner?
M
Marta Krzyzanowska17h ago
Is this LDT, 510(k), or De Novo pathway? And where does the raw eye-tracking data live, because that's biometric under most frameworks.
O
Omar Fakhoury17h ago
How small is the team shipping this? Hardware plus clinical plus ML is usually 40 people and you two look like four in the video.
L
Lior Benzaquen17h ago
The cut from 'you've had it 15 years' to the product shot at 0:08 is textbook retention. Whoever edited that understands the algorithm.
E
Eric Olatunji17h ago
Was the demo in the video pre-recorded or live inference? The latency on the overlay looked suspiciously clean.
D
Dmitri Volkov17h ago
Any plan to expose results via API for health systems, or is this strictly a closed clinical workflow? Asking for an EHR integration I may or may not be building.
K
kerning.goblin17h ago
The logotype is clean but the 'a' in Saccade is kissing the 'c' at smaller sizes. Otherwise the palette is doing the Lord's work.
R
Raj Venkatesan17h ago
Love it. One more thing: pair this with a longitudinal at-home version and you own the entire monitoring arc post-diagnosis.
F
Francesca Boateng17h ago
What does the patient actually see on the screen for the first 10 seconds? That onboarding will make or break clinic adoption more than any sensitivity number.
Y
Yuki H.17h ago
Naive question but what happens if the patient wears glasses or has a lazy eye? Does that break the signal?
A
Aarav building17h ago
Been noodling on an eye-tracking diagnostics idea for months and you guys just shipped it. Back to the drawing board I guess.
Work With Us
Book an intro call to explore our suite of services. We might have a waitlist.
Saccade Health
The world's earliest test for Alzheimer's biomarkers
The world's earliest test for Alzheimer's biomarkers
Tags
TLVC Rating
Community Rating
No ratings yet
to rate this launch.
Saccade is building a 15-minute VR-based assessment that screens for Alzheimer's by measuring oculomotor patterns, the small, involuntary eye movements that shift up to 15 years before symptoms appear . The test is designed for longevity clinics and works through a patent-pending attachment that connects to any VR headset on the market and captures eye movement patterns while patients perform visual tasks designed by neurologists. Those signals are then run against an ML model to produce a risk score that clinicians can act on. The timing matters because Alzheimer's testing today is bottlenecked around the onset of symptoms, when the damage is already done, and the FDA-approved drugs released in 2024 only slow the disease rather than reverse it . Catching the earliest biomarkers opens a longer window for intervention, and Saccade routes classified patients to the new drug regimens and to longevity or neurology practices depending on their stage of decline. The company is based in San Francisco and part of Y Combinator's Fall 2026 batch . It was founded by Shreyas Bhardwaj , who previously built medical devices for hospitals and worked as a soft robotics researcher before starting the company.
Comments (15)
The 15-year hook in the first line is doing serious work. Half the people in that reply thread learned something new before the second sentence.
Eye-tracking for prodromal AD has decades of literature behind it but almost nothing shipped to clinics. Curious which saccadic metrics you're keying on, antisaccade latency or something more composite?
The cruelest diseases are the ones that steal time you didn't know you had. Giving people back 15 years of warning is the whole game.
Market shrinks the second a disease-modifying therapy actually works at scale. You're racing against your own TAM.
Been watching this space for a while and the moat is distribution into neurology clinics, not the test itself. Who's your first channel partner?
Is this LDT, 510(k), or De Novo pathway? And where does the raw eye-tracking data live, because that's biometric under most frameworks.
How small is the team shipping this? Hardware plus clinical plus ML is usually 40 people and you two look like four in the video.
The cut from 'you've had it 15 years' to the product shot at 0:08 is textbook retention. Whoever edited that understands the algorithm.
Was the demo in the video pre-recorded or live inference? The latency on the overlay looked suspiciously clean.
Any plan to expose results via API for health systems, or is this strictly a closed clinical workflow? Asking for an EHR integration I may or may not be building.
The logotype is clean but the 'a' in Saccade is kissing the 'c' at smaller sizes. Otherwise the palette is doing the Lord's work.
Love it. One more thing: pair this with a longitudinal at-home version and you own the entire monitoring arc post-diagnosis.
What does the patient actually see on the screen for the first 10 seconds? That onboarding will make or break clinic adoption more than any sensitivity number.
Naive question but what happens if the patient wears glasses or has a lazy eye? Does that break the signal?
Been noodling on an eye-tracking diagnostics idea for months and you guys just shipped it. Back to the drawing board I guess.